One BioMed, A*Star Collaborate to Develop POC MDx Platform, Syndromic Assays

May 30, 2017

|

NEW YORK (GenomeWeb) –One BioMed and A*Star’s Genome Institute of Singapore (GIS) said on Monday that they have established a joint laboratory to develop molecular diagnostic assays for the Asian clinical infectious disease testing market.

The joint laboratory will focus on the development and integration of initial assays for One BioMed's platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

One BioMed, A*Star Collaborate to Develop POC MDx Platform, Syndromic Assays

To read the full story....

Breaking News

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Fulgent Inks $125M Equity Distribution Agreement With Piper Sandler

FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

What's Popular?

Babson Diagnostics Raises $13.7M In Series A Financing

FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

Sponsorships